• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic’s renal denervation system demonstrates better blood pressure control, time in range

Medtronic’s renal denervation system demonstrates better blood pressure control, time in range

May 17, 2022 By Sean Whooley

Symplicity Spyral renal denervation system Medtronic
The Symplicity Spyral renal denervation system delivers energy to the nerves leading to the kidneys, which help regulate blood pressure. [Image courtesy of Medtronic]
Medtronic (NYSE:MDT) announced today that new data supports the use of its Symplicity Spyral renal denervation (RDN) system.

As part of the medtech giant’s Spyral HTN global clinical program, three-year data from the Spyral HTN-ON MED and GSR-Define trials were presented at EuroPCR 2022 as late-breaking clinical trials demonstrating the benefit of the Symplicity blood pressure procedure with Simplicity Spyral.

The Medtronic RDN minimally invasive procedure delivers radiofrequency energy to specific nerves near the kidneys that can become overactive and cause high blood pressure. It is currently limited to investigational use in the United States, Japan and Canada.

Results from the first 80 patients in the Spyral HTN-ON MED trial show improved blood pressure control with significantly higher time in target range (TTR) after radiofrequency RDN when compared to sham through three years, regardless of anti-hypertensive medications.

TTR for patients treated with RDN registered at 33.7%, nearly doubling (18.8%) the outcome for sham patients through three years, according to a news release.

In the GSR-Define study, it was observed that improved blood pressure control after radiofrequency RDN is associated with a lower risk of major adverse cardiovascular events (MACE) through three years, with RDN patients spending 34.9% of the time in TTR over three years and a 16% drop in MACE associated with every 10% increase in TTR at six months.

The GSR-Define trial covered 3,000 patients from the GSR study and is enrolling up to an additional 2,000 patients across 222 sites in 42 countries.

“The data presented today at EuroPCR provide meaningful insights into the benefits of RDN through a patient lens, looking at how much time they spend within a target BP range,” Medtronic SVP and President of the Coronary and Renal Denervation Business Jason Weidman said in the release. “This new data reinforces RDN’s effectiveness as a complementary solution for achieving better blood pressure control and reducing cardiovascular risk.”

In October 2021, Medtronic announced that the Spyral HTN-ON MED study of Symplicity Spyral would continue into 2022 after lacking the positive results needed to end enrollment early. Despite that setback, company officials remain confident that renal denervation is still a multi-billion dollar market opportunity. CEO Geoff Martha said in January that Medtronic expects follow-up with completion in the second half of this calendar year, followed by submitting data to the FDA for approval.

Needham & Co. analysts in March reiterated their “Buy” rating for Medtronic stock, saying that renal denervation could still be a big opportunity for the company.

Filed Under: Blood Management, Cardiovascular, Clinical Trials, Featured, News Well Tagged With: Medtronic, renal denervation

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy